DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyung Hwan | ko |
dc.contributor.author | Cho, Jinhyun | ko |
dc.contributor.author | Ku, Bo Mi | ko |
dc.contributor.author | Koh, Jiae | ko |
dc.contributor.author | Sun, Jong-Mu | ko |
dc.contributor.author | Lee, Se-Hoon | ko |
dc.contributor.author | Ahn, Jin Seok | ko |
dc.contributor.author | Cheon, Jaekyung | ko |
dc.contributor.author | Min, Young Joo | ko |
dc.contributor.author | Park, Su-Hyung | ko |
dc.contributor.author | Park, Keunchil | ko |
dc.contributor.author | Ahn, Myung-Ju | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.date.accessioned | 2019-04-24T13:13:13Z | - |
dc.date.available | 2019-04-24T13:13:13Z | - |
dc.date.created | 2019-04-22 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.citation | CLINICAL CANCER RESEARCH, v.25, no.7, pp.2144 - 2154 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | http://hdl.handle.net/10203/261483 | - |
dc.description.abstract | Purpose: To investigate blood-based dynamic biomarkers that predict responses to anti-programmed cell death protein 1 (PD-1) therapy in solid tumors. Experimental Design: Preplanned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631) in patients with metastatic or refractory thymic epithelial tumors (TETs; n = 31) who received pembrolizumab. The biomarker was further tested in an independent cohort of prospectively recruited patients with metastatic non-small cell lung cancer (NSCLC) who received pembrolizumab or nivolumab (NSCLC cohort 1; n = 33) and validated in an independent cohort of patients with NSCLC (NSCLC cohort 2; n = 46). Peripheral blood samples were obtained immediately before treatment (D0) and 7 days after the first dose (D7) and analyzed using multi-color flow cytometry. Results: A higher fold-change in the percentage of Ki-67(+) cells among PD-1(+)CD8(+) T cells 7 days after the first dose (Ki-67(D7/D0)) significantly predicted durable clinical benefit (DCB; P < 0.001) and prolonged progression-free survival (PFS; P = 0.027) in patients with TETs. Ki-67(D7/D0) >= 2.8 was also associated with better DCB, PFS, and overall survival (OS) in NSCLC cohort 1 (all P < 0.05). Ki-67(D7/D0) was subsequently validated in NSCLC cohort 2, and Ki-67(D7/D0) >= 2.8 significantly predicted better DCB (P = 0.001), PFS (P = 0.002), and OS (P = 0.037). Ki-67(D7/D0) had a low correlation with tumor PD-L1 expression and combining both factors did not improve the predictive power of Ki-67(D7/D0). Conclusions: The proliferative response of peripheral blood PD-1(+)CD8(+) T cells, measured as the fold-change in the percentage of Ki-67(+) cells 7 days after treatment (Ki67(D7/D0)), may be a useful surrogate biomarker for predicting the response and prognosis to anti-PD-1 therapy in solid tumors. | - |
dc.language | English | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.title | The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors | - |
dc.type | Article | - |
dc.identifier.wosid | 000462991900018 | - |
dc.identifier.scopusid | 2-s2.0-85062771961 | - |
dc.type.rims | ART | - |
dc.citation.volume | 25 | - |
dc.citation.issue | 7 | - |
dc.citation.beginningpage | 2144 | - |
dc.citation.endingpage | 2154 | - |
dc.citation.publicationname | CLINICAL CANCER RESEARCH | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-18-1449 | - |
dc.contributor.localauthor | Park, Su-Hyung | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Cho, Jinhyun | - |
dc.contributor.nonIdAuthor | Ku, Bo Mi | - |
dc.contributor.nonIdAuthor | Koh, Jiae | - |
dc.contributor.nonIdAuthor | Sun, Jong-Mu | - |
dc.contributor.nonIdAuthor | Lee, Se-Hoon | - |
dc.contributor.nonIdAuthor | Ahn, Jin Seok | - |
dc.contributor.nonIdAuthor | Cheon, Jaekyung | - |
dc.contributor.nonIdAuthor | Min, Young Joo | - |
dc.contributor.nonIdAuthor | Park, Keunchil | - |
dc.contributor.nonIdAuthor | Ahn, Myung-Ju | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | IMMUNE-CHECKPOINT BLOCKADE | - |
dc.subject.keywordPlus | PD-1 BLOCKADE | - |
dc.subject.keywordPlus | SINGLE-ARM | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | MULTICENTER | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.